FOLH1 and prostate carcinoma: The success of 68Ga-THP-PSMA in clinical Phase I also indicates that 68Ga-THP-PSMA is expected to become another PET diagnostic imaging agent for prostate cancers after 68Ga-PSMA-11 [99].